Ngm biopharmaceuticals inc (NGM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Related party revenue

24,364

31,083

21,568

25,341

25,552

47,119

20,815

22,118

18,613

Operating expenses:
Research and development

38,439

41,954

28,953

28,819

29,527

28,941

24,473

22,846

19,454

General and administrative

6,595

6,423

5,612

6,229

5,367

5,122

4,811

3,458

3,874

Total operating expenses

45,034

48,377

34,565

35,048

34,894

34,063

29,284

26,304

23,328

Loss from operations

-20,670

-17,294

-12,997

-9,707

-9,342

13,056

-8,469

-4,186

-4,715

Interest income

1,175

1,554

1,984

2,044

1,110

1,013

966

891

752

Other income (expense), net

380

-201

96

-6

-36

96

-14

95

22

Net loss

-19,115

-15,941

-10,917

-7,669

-8,268

14,165

-7,517

-3,200

-3,941

Net loss per share, basic and diluted

-0.28

0.66

-0.17

-0.13

-1.21

2.23

-1.15

-0.52

-0.64

Weighted average shares used to compute net loss per share, basic and diluted

67,396

67,385

65,948

61,044

6,812

6,682

6,525

6,200

6,127